• LinusBio Launches ClearStrand-ASD That Detects Autism With a Single Hair Strand

    Feb 13 | Diagnostics World | Amid an industrywide shortage of workers and hospital capacity, a multimodal artificial intelligence (AI) platform providing real-time visibility into the clinical picture for patients is finding a national audience with health systems big and small who want to “make the right thing the easy thing to do” for their overburdened clinicians. More

  • Dual Biomarker Assay for Pancreatic Cancer to be Studied in CLIA Lab

    Feb 11 | Diagnostics World | Two glycans are better than one when it comes to detecting pancreatic cancer that currently lacks a biomarker capable of accurately and reliably spotting the disease. The gold standard biomarker CA19-9, approved by the U.S. Food and Drug Administration (FDA) for monitoring response to treatment, correctly identifies only 44% of cases but the addition of CA199.STRA ramped that up to 71% while maintaining a low false positive rate in a recent case control study. More

  • Wearables Could Enable Continuous Monitoring of Inflammatory Diseases

    Feb 05 | Diagnostics World | Physiological changes in the body driven by inflammation, as happens with inflammatory bowel disease (IBD) and rheumatoid arthritis, can be “easily and passively” measured with commercially available wearable devices, according to gastroenterologist Robert Hirten, M.D., associate professor of medicine and artificial intelligence and human health at the Icahn School of Medicine at Mount Sinai. More

  • High-Value Opportunities for Multimodal AI in Clinical Care and Research

    Feb 04 | Diagnostics World | Amid an industrywide shortage of workers and hospital capacity, a multimodal artificial intelligence (AI) platform providing real-time visibility into the clinical picture for patients is finding a national audience with health systems big and small who want to “make the right thing the easy thing to do” for their overburdened clinicians. More

  • Follow the Money: OTC Diagnostics, Breath Biopsies, AI

    Jan 29 | Diagnostics World | January’s funding focused on at-home cancer diagnostics, treatments for autoimmune disorders, and gene therapy for ophthalmology, Hepatitis B, and more. More

  • New Diagnostic Tools, MRD panels, New 23andMe Research Product

    Jan 28 | Diagnostics World News | PathAI and Discovery Life Sciences launch partnership; new diagnostic tools for epilepsy, syphilis; OGT launches MRD panel; more. More

  • Quanterix Launches New Platform for Alzheimer’s Treatment Development, Big Plans for 2025

    Jan 23 | Diagnostics World | At this year’s J.P. Morgan Healthcare Conference, Masoud Toloue, CEO of Quanterix, presented his company’s achievements of 2024, the acquisition of Akoya Biosciences, and their plans for the new year. Toloue opened with Quanterix’s mission, “The mission at Quanterix is to create the tools to enable discovery and better health.” More

  • Mount Sinai Develops Diagnostic AI Tool to Predict Cancer Patient Response to ICI Therapy

    Jan 22 | Diagnostics World | Researchers at the Tisch Cancer Institute at Mount Sinai, in collaboration with Memorial Sloan Kettering Cancer Center (MSKCC), have unveiled SCORPIO, an artificial intelligence (AI) tool designed to predict cancer patients’ responses to immune checkpoint inhibitor (ICI) therapy. By focusing on diagnostic capabilities, SCORPIO uses routine blood tests and clinical data to identify patterns that correlate with treatment outcomes, offering an innovative approach to guiding immunotherapy decisions. More

  • At JPM: PacBio Turns Attention to LDTs

    Jan 21 | Diagnostics World | PacBio’s president Christian Henry gave the sequencing company’s 43rd Annual J.P. Morgan Healthcare Conference address last week. And while Oxford Nanopore and Illumina both doubled down on proteomics and a multi-omic future, Henry stayed focus on PacBio’s mission to enable the promise of genomics to better human health. More

  • Grail at JPM: Looking Forward to Study Readouts, Prepped for Scale

    Jan 15 | Diagnostics World | Grail presented for the first time at the 42rd Annual J.P. Morgan Healthcare conference today, and Bob Ragusa, CEO, took the stage. Grail was divested from Illumina and became an independent, publicly traded company in June 2024. But while the company structure has changed significantly in 2024, the mission has not, Ragusa said: detecting cancer early, when it can be cured. More
View more articles

 
DXX-Industry-spotlight

merck


Custom Diagnostic Antibody Development & Manufacturing Services

Overcome Process Challenges by outsourcing your custom antibody production to us. How partnering with an antibody production expert can improve your assay, accelerate launch, and maintain your manufacturing.

Learn more